XML 44 R34.htm IDEA: XBRL DOCUMENT v3.25.3
Business Segment (Tables)
 9 Months Ended
Sep. 30, 2025
Segment Reporting [Abstract]  
Schedule of Net Sales Information by Product Line These product lines' net sales are as follows:
Three Months Ended September 30,Nine Months Ended September 30,
 2025202420252024
Orthopedic surgery$138,193 $130,537 $417,216 $404,986 
General surgery199,733 186,164 584,310 556,085 
Consolidated net sales$337,926 $316,701 $1,001,526 $961,071 
Schedule of Segment Reporting Information, by Segment The following table includes significant segment expenses:
Three Months Ended September 30,Nine Months Ended September 30,
2025202420252024
Net sales
$337,926 $316,701 $1,001,526 $961,071 
Cost of sales
171,807 137,706 469,336 426,383 
Salesforce and commission expense
59,404 55,124 175,760 167,720 
Marketing expense
16,915 16,053 49,782 48,002 
Distribution expense
13,085 12,039 38,270 36,831 
General and administrative expense
31,941 28,396 97,609 89,388 
Stock-based compensation expense
4,585 6,123 23,352 19,336 
Amortization expense
7,233 7,158 21,597 21,466 
Non-cash adjustments to fair value of contingent consideration liability1,341 (27,049)3,504 (42,267)
Research and development expense
13,901 13,558 40,985 41,250 
Interest expense
7,606 9,252 23,716 28,440 
Other expense
— — 418 — 
Provision for income taxes
1,414 7,471 11,548 20,719 
Other segment items(a)
5,835 1,886 15,333 5,135 
Net income
$2,859 $48,984 $30,316 $98,668 
(a)Other segment items consist of (i) third party services pertaining to review of potential issues with certain royalty payments to surgeons involved in design teams during the three and nine months ended September 30, 2025 and 2024; (ii) cash compensation costs related to advisory services provided by our former Chief Executive Officer during the nine months ended September 30, 2025; (iii) consulting fees related to operational optimization during the three and nine months ended September 30, 2025; (iv) gain on the sale of a product line during the nine months ended September 30, 2025; and (v) restructuring related costs and income related to the termination of a distributor agreement during the nine months ended September 30, 2024.